Cover Page
Cover Page | Oct. 13, 2020 |
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Oct. 13, 2020 |
Entity Registrant Name | Axovant Gene Therapies Ltd. |
Entity Incorporation, State or Country Code | D0 |
Entity File Number | 001-37418 |
Entity Tax Identification Number | 98-1333697 |
Entity Address, Address Line One | Suite 1, 3rd Floor |
Entity Address, Address Line Two | 11-12 St. James's Square |
Entity Address, City or Town | London |
Entity Address, Postal Zip Code | SW1Y 4LB |
Entity Address, Country | GB |
Country Region | 44 |
City Area Code | 203 |
Local Phone Number | 997 8931 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Shares, par value $0.00001 per share |
Trading Symbol | AXGT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
Amendment Flag | false |
Entity Central Index Key | 0001636050 |